Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Xenon Pharmaceuticals Inc. - Common Shares
(NQ:
XENE
)
44.49
-0.33 (-0.74%)
Streaming Delayed Price
Updated: 4:00 PM EST, Jan 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Xenon Pharmaceuticals Inc. - Common Shares
< Previous
1
2
3
4
5
6
7
8
Next >
Xenon to Present at BofA Securities 2024 CNS Therapeutics Virtual Conference
October 02, 2024
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon Showcases Azetukalner Data at 15th European Epilepsy Congress
September 09, 2024
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon Expands Leadership Team with Matthew D. Ronsheim, Ph.D. as Chief Operating Officer
August 12, 2024
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Earnings Scheduled For February 29, 2024
↗
February 29, 2024
Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million.
Via
Benzinga
Earnings Outlook For Xenon Pharmaceuticals
↗
February 28, 2024
Via
Benzinga
4 Analysts Have This to Say About Xenon Pharmaceuticals
↗
December 08, 2023
Via
Benzinga
XENE Stock Earnings: Xenon Pharmaceuticals Misses EPS for Q2 2024
↗
August 08, 2024
XENE stock results show that Xenon Pharmaceuticals missed analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
Xenon Reports Q2 2024 Financial Results and Business Update
August 08, 2024
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon to Report Q2 2024 Financial Results on August 8, 2024
August 01, 2024
Conference Call and webcast scheduled at 4:30 pm ET
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
June 05, 2024
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon Pharmaceuticals Presents Data from Phase 2 X-NOVA Clinical Trial of Azetukalner in Major Depressive Disorder at the American Society of Clinical Psychopharmacology 2024 Annual Meeting
May 28, 2024
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
XENE Stock Earnings: Xenon Pharmaceuticals Beats EPS for Q1 2024
↗
May 09, 2024
XENE stock results show that Xenon Pharmaceuticals beat analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
Xenon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 09, 2024
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon Pharmaceuticals to Present at the BofA Securities Health Care Conference 2024
May 08, 2024
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon Pharmaceuticals to Present at the 2024 RBC Capital Markets Global Healthcare Conference
May 07, 2024
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss First Quarter 2024 Financial Results and Provide Corporate Update
May 02, 2024
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon Pharmaceuticals Showcases XEN1101 at the American Academy of Neurology 2024 Annual Meeting
April 16, 2024
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon Pharmaceuticals to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
April 10, 2024
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon Pharmaceuticals to Present at the 23rd Annual Needham Virtual Healthcare Conference
April 04, 2024
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon Pharmaceuticals to Present at Stifel 2024 Virtual CNS Days
March 12, 2024
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon Pharmaceuticals to Present at Leerink Partners Global Biopharma Conference 2024
March 05, 2024
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
February 29, 2024
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update
February 22, 2024
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
3 Biotech Stocks That Could Be Multibaggers in the Making: February Edition
↗
February 21, 2024
Now could be the time to start looking into these biotech stocks as there are imminent approvals on their clinical trials.
Via
InvestorPlace
This Analyst Is Bullish On Biohaven's Approach in Neuro-Psych Space
↗
February 16, 2024
Biohaven's potential with RBC Capital Markets' optimistic outlook.. RBC sees blockbuster potential of $3.2 billion across epilepsy and mood disorders. Anticipate significant developments in lead asset...
Via
Benzinga
Xenon Pharmaceuticals Outlines Key Milestone Opportunities for 2024
January 08, 2024
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Bristol Myers Squibb’s big buys: $18.1 billion in 2 biotech deals
December 29, 2023
Bristol Myers announced two acquisitions in a week. The pharma giant is boosting its neuroscience pipeline with Karuna and its oncology pipeline with RayzeBio.
Via
MarketBeat
Xenon Pharmaceuticals Announces Closing of $345.0 Million Upsized Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
December 04, 2023
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon Pharmaceuticals Provides Updates on Neurology Pipeline Programs at the Annual Meeting of the American Epilepsy Society (AES 2023)
December 02, 2023
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
